Survodutide (development code BI 456906) is a synthetic peptide developed by Boehringer Ingelheim based on mammalian oxyntomodulin, simultaneously targeting glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Its core objective is metabolic remodeling-not just helping you lose weight, but also addressing metabolic indicators such as liver fat, visceral fat, blood sugar, blood pressure, and blood lipids.
Core Mechanism:
Survodutide features C18 fatty acid acylation modification, which binds to serum albumin, significantly prolonging its half-life and exhibiting extremely high long-term stability within the system. The molecules activate dual receptor pathways in a balanced ratio: the GLP-1 receptor pathway is responsible for glucose-dependent insulin secretion, inhibiting abnormal glucagon release, and delaying gastric emptying, thereby reducing food intake at the source, stabilizing blood sugar control, and improving insulin resistance; the GCGR glucagon receptor pathway primarily enhances systemic energy expenditure, acting directly on the liver to accelerate fatty acid breakdown in hepatocytes, reduce visceral lipid accumulation, and simultaneously inhibit the progression of liver inflammation and fibrosis.
This synergistic dual-pathway approach achieves a triple regulation of "intake control + energy expenditure enhancement + liver protection and lipid reduction," which is the core reason why it exhibits a more prominent phenotype in metabolic disorders and hepatic steatosis models compared to ordinary GLP-1 monopeptides.
Applicable research scenarios: Research on energy homeostasis mechanisms in obesity and metabolic syndrome; experiments on blood glucose regulation and insulin resistance models in type 2 diabetes; investigation of the mechanisms of non-alcoholic fatty liver disease (NAFLD), hepatic steatosis, and liver fibrosis in MASLD; synergistic peptide-dual-receptor pathway comparison experiments; research on long-acting metabolic peptide structural modification and pharmacodynamic gradient screening.
Storage
Freeze-dried powder: Stable for approximately 2 years at −20℃, sealed, protected from light, and with a desiccant. Short-term working storage at 2–8℃ is also acceptable, but do not place it on the refrigerator door shelf or next to food. Even slight temperature fluctuations will cause the glucagon-binding domains to subtly clump together-this is invisible to the naked eye, and you won't even realize the receptor affinity has dropped by 40%.
Reconstitute using only BAC water (0.9% benzyl alcohol). Slowly push along the wall, gently roll for 60–90 seconds. Do not shake, as acylated peptides dissolve more slowly than smaller peptides. A correctly prepared solution should be clear and colorless; discard any that is cloudy, flocculent, or contains particles.
5 mg + 2 mL → 2.5 mg/mL; Use the liquid within 28–30 days at 2–8℃, protected from light. Never freeze; a single freeze-thaw cycle will damage disulfide bonds and acylated side chains, rendering the entire bottle unusable.
Take it out of the refrigerator and let it sit at room temperature for 15 minutes before opening the lid to prevent condensation from getting into the bottle. In summer, if the bottle is still warm from shipping and there are no ice packs, it's fine for research use, but if you're just applying it to your body, it will dissipate.
Acylated dual agonists are more sensitive to room temperature than regular GLP-1 powder: at 22–24℃, after 12 hours, GCGR affinity drops by 35–40%, while the GLP-1 end remains active. The result is "only suppressing appetite without burning liver fat," leading to a weight plateau at 7–9%, which may actually be due to peptide degradation.
Regarding contraindications, individuals with a personal or family history of medullary thyroid carcinoma (MTC) are absolutely contraindicated-this is a black box warning for the entire GLP-1 receptor agonist class, with no room for negotiation. Those with a history of pancreatitis, severe gastrointestinal diseases (such as gastroparesis), or gallbladder disease should also be extremely cautious. Pregnant women, breastfeeding mothers, and adolescents under 18 years of age are currently advised against using it.
Another point many people easily overlook is that even the strongest medication is only an adjunct treatment; it must be combined with a low-calorie diet and exercise. Expecting to take an injection once a week and then eat and drink whatever you want? Weight rebound is only a matter of time. Furthermore, appetite will return after stopping the medication, and gastric emptying speed will also resume. If you don't change your lifestyle, the weight you lost will eventually come back.
Hot Tags: 99% premium peptide powder, small bottle, survodutide. cas: 2805997-46-8, China 99% premium peptide powder, small bottle, survodutide. cas: 2805997-46-8 manufacturers, suppliers, factory
